Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
Addex Therapeutics(ADXN) Newsfilter·2024-06-06 13:00
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024. Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2024 financial results and provided a corporate update. "Building on the recent Neurosterix transaction, which extended our cas ...